BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Prototypes - ECPv6.7.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prototypes
X-ORIGINAL-URL:https://prototypes.tristar.solutions
X-WR-CALDESC:Events for Prototypes
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20200308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20201101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20210314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20211107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T150000
DTEND;TZID=America/Chicago:20210614T154500
DTSTAMP:20260616T004921
CREATED:20210211T222922Z
LAST-MODIFIED:20210415T151203Z
UID:477-1623682800-1623685500@prototypes.tristar.solutions
SUMMARY:Simplifying Diabetes Management—Advancing Innovation Across Outcomes\, Patient Experience\, and Support with the Guardian™ Connect Continuous Glucose Monitoring (CGM) System (U.S. Only) (This Product Theater is Pre-Recorded)
DESCRIPTION:Please join us for a virtual product theater on Medtronic’s cutting-edge Guardian™ Connect continuous glucose monitoring (CGM) technology and the role it plays in virtual diabetes care. You will hear from Dr. Amit Bhargava\, MD about real-world outcomes and case studies of patients using the Guardian™ Connect system with the Sugar.IQ™ diabetes assistant. This will be followed by a unique opportunity to observe a virtual telehealth conversation between Dr. Jason Baker\, MD and his patient\, Sam Talbot – as they walk you through their journey navigating diabetes management during COVID-19.Presenters: Sean SalmonExecutive Vice President and PresidentMedtronic DiabetesAmit Bhargava\, MD\, FACScThe Center for Diabetes and Endocrine Health of Allegheny General HospitalSam TalbotCelebrity Chef and T1 diabetes patientJason Baker\, MDAssistant Professor of Clinical Medicine and Attending EndocrinologistNew York-Presbyterian/Weill Cornell Medical CenterNew York\, NY
URL:https://prototypes.tristar.solutions/event/simplifying-diabetes-management-advancing-innovation-across-outcomes-patient-experience-and-support-with-the-guardian-connect-continuous-glucose-monitoring-cgm-system-u-s-only/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T123000
DTEND;TZID=America/Chicago:20210614T133000
DTSTAMP:20260616T004921
CREATED:20210211T222817Z
LAST-MODIFIED:20210415T173531Z
UID:440-1623673800-1623677400@prototypes.tristar.solutions
SUMMARY:Break the Sequential T2DM Treatment Pattern in Adult Patients with High A1C (≥9%) on OADs\, or Uncontrolled on GLP-1 Ras\, and get them to Goal (This Product Theater is Pre-Recorded)
DESCRIPTION:Presenter: Jeremy Pettus\, MDAssistant Professor of MedicineDivision of EndocrinologyUniversity of California\, San DiegoSan Diego\, CA
URL:https://prototypes.tristar.solutions/event/break-the-sequential-t2dm-treatment-pattern-in-adult-patients-with-high-a1c-%e2%89%a59-on-oads-or-uncontrolled-on-glp-1-ras-and-get-them-to-goal-this-product-theater-is-pre-recorded/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T123000
DTEND;TZID=America/Chicago:20210614T133000
DTSTAMP:20260616T004921
CREATED:20210211T222445Z
LAST-MODIFIED:20210415T151305Z
UID:329-1623673800-1623677400@prototypes.tristar.solutions
SUMMARY:Understanding Chronic Kidney Disease in Type 2 Diabetes—The Risks\, Recognition\, and Clinical Management (This Product Theater is Presented Live. It Will Not Be Available On Demand)
DESCRIPTION:Chronic Kidney Disease (CKD) develops in a substantial proportion of patients with type 2 diabetes (T2D) and significantly increases risk for adverse cardiovascular and renal outcomes. Multiple factors can contribute to the development and progression of CKD in T2D\, although understanding of the etiology continues to evolve. The deleterious impact of CKD in T2D progresses over time\, but consequences emerge in early stage disease\, raising the importance of adherence to guideline recommendations for diagnostic screening\, continued monitoring\, and coordination of care across specialties for patients with CKD and T2D.Presenter: Luiza Caramori\, MD\, PhD\, MScAssociate Professor of Medicine\, Division of Diabetes\, Endocrinology and MetabolismUniversity of MinnesotaMinneapolis\, MN
URL:https://prototypes.tristar.solutions/event/understanding-chronic-kidney-disease-in-type-2-diabetes-the-risks-recognition-and-clinical-management-this-product-theater-is-presented-live-it-will-not-be-available-on-demand/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T123000
DTEND;TZID=America/Chicago:20210614T133000
DTSTAMP:20260616T004921
CREATED:20210211T221852Z
LAST-MODIFIED:20210415T151313Z
UID:144-1623673800-1623677400@prototypes.tristar.solutions
SUMMARY:Renal and Cardiovascular Outcomes in Adults with Diabetic Nephropathy (i.e.\, DKD) and Type 2 Diabetes (U.S. Only) (This Product Theater is Presented Live. It Will Not Be Available On Demand)
DESCRIPTION:Topics include:•Renal and cardiovascular outcomes and overall safety profile in adults with diabetic nephropathy(i.e.\, diabetic kidney disease) and type 2 diabetes•Important Safety Information\, followed by a question-and-answer sessionPresenter: Yehuda Handelsman\, MD\, FACP\, FNLA\, FASPC\, MACEEndocrinologistMedical Director & Principal InvestigatorMetabolic Institute of AmericaTarzana\, CA
URL:https://prototypes.tristar.solutions/event/renal-and-cardiovascular-outcomes-in-adults-with-diabetic-nephropathy-i-e-dkd-and-type-2-diabetes-u-s-only-this-product-theater-is-presented-live-it-will-not-be-available-on-demand/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T101500
DTEND;TZID=America/Chicago:20210614T110000
DTSTAMP:20260616T004921
CREATED:20210211T222310Z
LAST-MODIFIED:20210415T151323Z
UID:284-1623665700-1623668400@prototypes.tristar.solutions
SUMMARY:Considerations for Glycemic Control—Choosing a Basal Insulin for Patients with Diabetes (This Product Theater is Pre-Recorded)
DESCRIPTION:Presenter: Helen Baron\, MD\, CCDMedical Director\, Diabetes ServicesEisenhower Diabetes and EndocrinologyEisenhower Medical AssociatesRancho Mirage\, CA
URL:https://prototypes.tristar.solutions/event/considerations-for-glycemic-control-choosing-a-basal-insulin-for-patients-with-diabetes-this-product-theater-is-pre-recorded/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210614T101500
DTEND;TZID=America/Chicago:20210614T110000
DTSTAMP:20260616T004921
CREATED:20210211T222107Z
LAST-MODIFIED:20210420T191209Z
UID:219-1623665700-1623668400@prototypes.tristar.solutions
SUMMARY:VASCEPA® (icosapent ethyl)—Elevating the Standard of Care (This Product Theater is Presented Live)
DESCRIPTION:There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program\, we will review data from a practice changing trial that provides a new therapeutic option to elevate the current standard of care.Presenter: Yehuda Handelsman\, MD\, FACP\, FNLA\, FASPC\, MACE EndocrinologistMedical Director & Principal InvestigatorMetabolic Institute of AmericaTarzana\, CA
URL:https://prototypes.tristar.solutions/event/sl-test-006/
CATEGORIES:Product Theaters
LOCATION:https://youtu.be/ScMzIvxBSi4
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210613T123000
DTEND;TZID=America/Chicago:20210613T133000
DTSTAMP:20260616T004921
CREATED:20210211T222726Z
LAST-MODIFIED:20210415T151411Z
UID:413-1623587400-1623591000@prototypes.tristar.solutions
SUMMARY:Are We Waiting Too Long to Start a GLP-1RA in Adult Patients with T2D? (For Non-U.S. HCPs Only) (This Product Theater is Pre-Recorded)
DESCRIPTION:This presentation provides an overview of a GLP-1RA for adult patients with T2D\, including an in-depth review of head-to-head data from the clinical trial program. The results from a CVOT will also be reviewed. Presenter: Adie Viljoen\, MB\, ChB\, FCP\, MD\, FRCPath\, MBAConsultant Metabolic PhysicianThe Lister HospitalStevenage\, United Kingdom
URL:https://prototypes.tristar.solutions/event/are-we-waiting-too-long-to-start-a-glp-1ra-in-adult-patients-with-t2d-for-non-u-s-hcps-only-this-product-theater-is-pre-recorded/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210613T123000
DTEND;TZID=America/Chicago:20210613T133000
DTSTAMP:20260616T004921
CREATED:20210211T222416Z
LAST-MODIFIED:20210415T151417Z
UID:315-1623587400-1623591000@prototypes.tristar.solutions
SUMMARY:Thinking Beyond Glycemia—The Importance of Managing Heart Failure Risks in Type 2 Diabetes (This Product Theater is Pre-Recorded)
DESCRIPTION:We will examine the risk of heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial\, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D and CV disease or multiple CV risk factors. We’ll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.Presenter: Serge Jabbour\, MD\, FACP\, FACEProfessor of MedicineDirector\, Division of Endocrinology\, Diabetes & Metabolic DiseaseSidney Kimmel Medical College at Thomas Jefferson UniversityPhiladelphia\, PA
URL:https://prototypes.tristar.solutions/event/thinking-beyond-glycemia-the-importance-of-managing-heart-failure-risks-in-type-2-diabetes-this-product-theater-is-pre-recorded/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20210317T101500
DTEND;TZID=America/Chicago:20210613T110000
DTSTAMP:20260616T004921
CREATED:20210211T222122Z
LAST-MODIFIED:20210416T211318Z
UID:226-1615976100-1623582000@prototypes.tristar.solutions
SUMMARY:Enabling Telemedicine and Remote Monitoring With the Freestyle Libre 14 Day System (This Product Theater is Pre-Recorded)
DESCRIPTION:Join us to learn about the #1 CGM worldwide† used by more than 2 million people*\, the FreeStyleLibre 14-day system.Daniel Einhorn\, MD\, FACP\, FACE\, will share how he utilizes the FreeStyleLibre 14-day system to enable diabetes management and monitoring of patients remotely. Dr. Einhorn will also share real-world telemedicine patient cases.Presenter: Daniel Einhorn\, MD\, FACP\, FACEMedical Director\, Scripps Whittier Diabetes InstituteClinical Professor of Medicine\, University of California\, San DiegoPresident\, Diabetes and Endocrine AssociatesSan Diego\, CA†Data based on the number of users worldwide for FreeStyle Libre personal CGM compared to the number of users for other leading personal CGM brands.*Data based on the number of users worldwide for FreeStyle Libre products. In the United States product is branded FreeStyle Libre 14-day SystemThis program is sponsored by Abbott\, the speaker or speakers are presenting on behalf of Abbott and the content of the program is in compliance with applicable regulatory requirements.
URL:https://prototypes.tristar.solutions/event/enabling-telemedicine-and-remote-monitoring-with-the-freestyle-libre-14-day-system-this-product-theater-is-pre-recorded/
CATEGORIES:Product Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20200101T101500
DTEND;TZID=America/Chicago:20200101T110000
DTSTAMP:20260616T004921
CREATED:20210211T223900Z
LAST-MODIFIED:20210420T191135Z
UID:609-1577873700-1577876400@prototypes.tristar.solutions
SUMMARY:VASCEPA® (icosapent ethyl)—Elevating the Standard of Care
DESCRIPTION:YEHUDA HANDELSMAN\, Tarzana\, CA
URL:https://prototypes.tristar.solutions/event/sl-test-001/
CATEGORIES:Product Theaters
LOCATION:https://prototypes.tristar.solutions/event/sl-test-001/
END:VEVENT
END:VCALENDAR